A detailed history of Palo Alto Investors LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Palo Alto Investors LP holds 2,523,956 shares of ACAD stock, worth $41.9 Million. This represents 5.34% of its overall portfolio holdings.

Number of Shares
2,523,956
Previous 2,418,841 4.35%
Holding current value
$41.9 Million
Previous $39.3 Million 1.18%
% of portfolio
5.34%
Previous 4.98%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.14 - $19.14 $1.59 Million - $2.01 Million
105,115 Added 4.35%
2,523,956 $38.8 Million
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $56,988 - $71,801
3,898 Added 0.16%
2,418,841 $39.3 Million
Q1 2024

May 15, 2024

BUY
$17.79 - $30.86 $95,834 - $166,242
5,387 Added 0.22%
2,414,943 $44.7 Million
Q4 2023

Feb 14, 2024

BUY
$20.78 - $31.77 $78,195 - $119,550
3,763 Added 0.16%
2,409,556 $75.4 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $480,199 - $615,550
29,424 Added 1.24%
2,405,793 $45.3 Million
Q4 2022

Feb 14, 2023

BUY
$14.2 - $18.63 $9.91 Million - $13 Million
698,173 Added 41.6%
2,376,369 $37.8 Million
Q2 2022

Aug 15, 2022

SELL
$13.01 - $27.22 $7.46 Million - $15.6 Million
-573,638 Reduced 25.47%
1,678,196 $23.6 Million
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $1.8 Million - $2.37 Million
-86,043 Reduced 3.68%
2,251,834 $54.5 Million
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $910,728 - $2 Million
36,400 Added 1.58%
2,337,877 $60.3 Million
Q4 2020

Feb 16, 2021

BUY
$41.04 - $56.79 $19.3 Million - $26.6 Million
469,177 Added 25.61%
2,301,477 $123 Million
Q3 2020

Nov 16, 2020

BUY
$36.42 - $57.0 $9.74 Million - $15.2 Million
267,400 Added 17.09%
1,832,300 $75.6 Million
Q2 2020

Aug 14, 2020

SELL
$39.26 - $52.73 $2.62 Million - $3.51 Million
-66,624 Reduced 4.08%
1,564,900 $75.9 Million
Q1 2020

May 15, 2020

SELL
$31.65 - $46.87 $8.67 Million - $12.8 Million
-273,850 Reduced 14.37%
1,631,524 $68.9 Million
Q4 2019

Feb 14, 2020

SELL
$36.21 - $51.4 $9.82 Million - $13.9 Million
-271,303 Reduced 12.46%
1,905,374 $81.5 Million
Q3 2019

Nov 14, 2019

SELL
$22.22 - $44.01 $2.94 Million - $5.81 Million
-132,126 Reduced 5.72%
2,176,677 $78.3 Million
Q2 2019

Aug 14, 2019

BUY
$23.32 - $28.12 $1.41 Million - $1.7 Million
60,400 Added 2.69%
2,308,803 $61.7 Million
Q1 2019

Jul 30, 2019

BUY
$16.17 - $27.38 $36.4 Million - $61.6 Million
2,248,403 New
2,248,403 $60.4 Million
Q1 2019

May 15, 2019

SELL
$16.17 - $27.38 $32.8 Million - $55.5 Million
-2,026,063 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$14.32 - $22.92 $4.9 Million - $7.84 Million
341,883 Added 20.3%
2,026,063 $32.8 Million
Q3 2018

Nov 14, 2018

BUY
$13.03 - $21.81 $435,202 - $728,454
33,400 Added 2.02%
1,684,180 $35 Million
Q1 2018

May 15, 2018

BUY
$22.47 - $32.33 $219,082 - $315,217
9,750 Added 0.59%
1,650,780 $37.1 Million
Q3 2017

Nov 14, 2017

BUY
$29.49 - $38.37 $48.4 Million - $63 Million
1,641,030
1,641,030 $61.8 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.69B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Palo Alto Investors LP Portfolio

Follow Palo Alto Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.